Treatment of -mutated advanced or metastatic melanoma: rationale, current trials and evidence to date

Treatment of -mutated advanced or metastatic melanoma: rationale, current trials and evidence to date

The disease course of BRAF (v-raf murine sarcoma viral oncogene homolog B1)-mutant melanoma has been drastically improved by the arrival of targeted therapies. NRAS (neuroblastoma RAS viral oncogene homolog)-mutated melanoma represents 15–25% of all metastatic melanoma patients. It currently does no...

Full description

Bibliographic Details
Main Authors: Amélie Boespflug, Julie Caramel, Stephane Dalle, Luc Thomas
Format: Article
Language:English
Published: SAGE Publishing 2017-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758834017708160

Similar Items

Similar Items